John T. Treace, the Chief Executive Officer of Treace Medical Concepts, Inc. (NASDAQ:TMCI), has significantly expanded his direct ownership position in the company through a series of recent stock purchases. Over two consecutive trading days in June 2026, Mr. Treace acquired a total of 52,317 shares, with transaction values totaling $210,967. These trades occurred on June 10 and June 11, 2026, marking a deliberate increase in his personal stake in the medical technology firm.
On June 10, 2026, Mr. Treace purchased 29,430 shares of common stock. The acquisition was executed through multiple transactions, resulting in a weighted average price of $4.0240 per share. The individual transaction prices for this day ranged from a low of $3.9300 to a high of $4.1000. The following day, June 11, 2026, the CEO acquired an additional 22,887 shares. These subsequent purchases were also executed at varying prices, with a weighted average of $4.0434 per share and individual transaction prices spanning from $3.9600 to $4.1700. The cumulative effect of these two days of trading activity is a direct increase in his share count by 52,317 units.
Following these latest acquisitions, Mr. Treace's direct holdings in Treace Medical Concepts stand at 7,376,150 shares of common stock. This figure explicitly includes 542,784 restricted stock units. Beyond his direct ownership, Mr. Treace maintains indirect economic interests through various trusts and his spouse. His indirect holdings include 1,605,000 shares held directly by his spouse, 1,471,250 shares held by his spouse as a trustee of a trust, 1,839,063 shares where he serves as trustee, and 408,816 shares where he acts as co-trustee. Standard disclosure practices are in effect; Mr. Treace disclaims beneficial ownership of shares held by his wife directly or in trusts where she serves as trustee or co-trustee, as well as shares in trusts where he serves as trustee or co-trustee.
The timing of these insider purchases coincides with a period of notable price appreciation for TMCI shares. Recent market data indicates the stock has posted an 11.4% return over the past week and has surged 59.59% year-to-date as of the transaction dates. Market analysis from InvestingPro suggests that TMCI may be undervalued at its current trading levels. Investors seeking comprehensive data on TMCI and over 1,400 other US equities can access detailed Pro Research Reports through the InvestingPro platform.
These trading activities follow the release of Treace Medical Concepts' financial results for the first quarter of 2026. The company reported earnings that surpassed analyst expectations. Specifically, the company recorded an earnings per share (EPS) of -$0.28, which beat the consensus forecast of -$0.31. Revenue for the quarter reached $47.2 million, exceeding the anticipated $45.86 million. Despite beating estimates, the reported revenue represented a 10% decline compared to the same period in the previous year.
Corporate governance updates also occurred during this period. At the 2026 Annual Meeting of Stockholders, shareholders voted to elect Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan as Class II directors. Each nominee was selected for a three-year term concluding in 2029. The voting results showed strong support for the nominees: Berry received 33,804,407 votes in favor, Hanna received 30,856,965 votes, and Kiernan received 33,587,226 votes. Each nominee also faced 13,516,432 broker non-votes.
These developments collectively reflect recent operational and governance shifts within Treace Medical Concepts, drawing attention from market participants analyzing executive behavior, financial metrics, and board composition.